Chile vs Landlocked developing countries (LLDCs): Proportion of the target population who received the final dose
Chile
87.0%
in 2024
Landlocked developing countries (LLDCs)
44.0%
in 2024
Chile rank
16th
Landlocked developing countries (LLDCs) rank
17th
Proportion of the target population who received the final dose over time
- Chile
- Landlocked developing countries (LLDCs)
How they compare
Chile currently reports 87.0% against 44.0% in Landlocked developing countries (LLDCs), a difference of 43.0%.
That makes Chile's figure about 2.0 times Landlocked developing countries (LLDCs)'s.
Across all 10 years both countries report, Chile has been ahead every year.
Chile ranks 16th and Landlocked developing countries (LLDCs) ranks 17th of 108 countries.
Chile has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Chile | Landlocked developing countries (LLDCs) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 77.8% | 9.2% | 68.6% | Chile |
| 2020s | 74.6% | 28.2% | 46.4% | Chile |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received the final dose of, Chile or Landlocked developing countries (LLDCs)?
- Chile, at 87.0% against 44.0% in Landlocked developing countries (LLDCs) as of 2024.
- What is the difference in proportion of the target population who received the final dose of between Chile and Landlocked developing countries (LLDCs)?
- 43.0%, with Chile ahead.
- How many years of comparable data are there for Chile and Landlocked developing countries (LLDCs)?
- 10 years are reported by both, from 2015 to 2024.
- How do Chile and Landlocked developing countries (LLDCs) rank globally for proportion of the target population who received the final dose of?
- Chile ranks 16th and Landlocked developing countries (LLDCs) ranks 17th of 108 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received the final dose of human papillomavirus (HPV) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.